Immunovant director granted RSUs and stock options

Immunovant, Inc. director Jake Bauer reported receiving new equity awards as part of his compensation.

Rhea-AI Filing Summary

Immunovant, Inc. director Jake Bauer reported receiving new equity awards as part of his compensation. On April 7, 2026 he was granted 13,880 shares of Common Stock in the form of restricted stock units under the company’s 2019 Equity Incentive Plan. These RSUs vest in full on April 1, 2027, conditional on his continuous service, and each unit converts into one share, with an option to defer settlement under Rule 409A. He also received a stock option for 7,061 shares at an exercise price of $24.61 per share, expiring April 7, 2036, which will vest on April 1, 2027 on the same service condition. Following the stock grant, he directly owns 38,896 shares of Immunovant common stock.

Insider Trade Summary

Grant/Award: 20,941 shares

Grant/Award 2 txns

Insider Bauer Jake

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	7,061	$0.00	$0.00
Grant/Award	Common Stock	13,880	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 7,061 contracts (Direct); Common Stock — 38,896 shares (Direct)

Footnotes (2)

1. F1. These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.
2. F2. These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date.

Key Figures

RSU grant: 13,880 shares Stock option size: 7,061 shares Option exercise price: $24.61 per share +3 more

6 metrics

RSU grant 13,880 shares Restricted stock units granted April 7, 2026; vest April 1, 2027

Stock option size 7,061 shares Option grant on April 7, 2026; vest April 1, 2027

Option exercise price $24.61 per share Exercise price for 7,061-share stock option grant

Option expiration April 7, 2036 Expiration date of granted stock option

Shares held after grant 38,896 shares Common stock directly owned after RSU grant

RSU vesting date April 1, 2027 Full vesting date for 13,880 RSUs, subject to service

Key Terms

restricted stock units, 2019 Equity Incentive Plan, Rule 409A, continuous service

4 terms

restricted stock units financial

"These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2019 Equity Incentive Plan financial

"These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan")."

Rule 409A financial

"The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A."

continuous service financial

"The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Immunovant (IMVT) director Jake Bauer report?

Jake Bauer reported receiving equity awards, not open-market trades. He was granted 13,880 restricted stock units and a stock option for 7,061 shares at a $24.61 exercise price, both tied to future vesting and continuous service with Immunovant.

How many Immunovant (IMVT) shares does Jake Bauer hold after these grants?

After the April 7, 2026 stock grant, Jake Bauer directly owns 38,896 Immunovant common shares. This figure reflects his updated post-transaction holdings as disclosed, giving investors a snapshot of his current direct equity stake in the company.

When do Jake Bauer’s Immunovant (IMVT) RSUs and options vest?

Both the restricted stock units and the stock options granted to Jake Bauer vest in full on April 1, 2027. Vesting is conditioned on his continuous service with Immunovant through that date, aligning his compensation with longer-term company performance and tenure.

What are the terms of Jake Bauer’s Immunovant (IMVT) stock option grant?

The stock option covers 7,061 Immunovant shares at a $24.61 exercise price and expires on April 7, 2036. The underlying shares vest on April 1, 2027, contingent on Bauer’s continued service, providing long-dated equity incentives tied to the company’s future value.

How do Jake Bauer’s Immunovant (IMVT) RSUs work under the 2019 Equity Incentive Plan?

Each of the 13,880 RSUs represents a right to receive one Immunovant share once vested. They vest in full on April 1, 2027 if Bauer remains in continuous service, and he may elect to defer settlement of vested units, subject to Rule 409A requirements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/09/2026 - 04:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bauer Jake

(Last) (First) (Middle)

C/O IMMUNOVANT, INC.

1000 PARK FORTY PLAZA, SUITE 210

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunovant, Inc. [ IMVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/07/2026		A		13,880(1)	A	$0	38,896	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$24.61	04/07/2026		A		7,061		(2)	04/07/2036	Common Stock	7,061	$0	7,061	D

Explanation of Responses:

1. These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.

2. These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date.

Remarks:

	/s/ Tiago Girao, Attorney-in-Fact for Jake Bauer	04/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)